Thomas Ferkol, M.D.

Profile picture
Professor of Cell Biology and Physiology
Alexis Hartmann Professor of Pediatrics
Researcher, Pathobiology
Cell Biology & PhysiologyAllergy, Immunology and Pulmonary Medicine

phone: (314) 454-2694

Clinical Interests

Thomas Ferkol, MD is the Alexis Hartmann Professor of Pediatrics, Professor of Cell Biology and Physiology, and Director of the multidisciplinary Division of Pediatric Allergy, Immunology, and Pulmonary Medicine at the Washington University School of Medicine. Dr. Ferkol graduated from Case Western Reserve University (Cleveland, Ohio) in 1981, and he received his M.D. degree from the Ohio State University College of Medicine (Columbus, Ohio) in 1985. He was a pediatric resident at the University of North Carolina at Chapel Hill (1985-1988), where he also served as Chief Resident and Clinical Instructor (1988-1989). Dr. Ferkol returned to Case Western Reserve University in 1989 for fellowship training in pediatric pulmonology, and subsequently joined the faculty of Case Western Reserve University and Rainbow Babies and Children’s Hospital. Dr. Ferkol moved to Washington University School of Medicine in 2000, where he is currently Director of the Division of Pediatric Allergy, Immunology, and Pulmonary Medicine. He is the past director of the comprehensive Washington University Cystic Fibrosis Center, and directed premier clinical and research programs in cystic fibrosis. The Center is a member of the Cystic Fibrosis Foundation Therapeutics Development Network. An American Lung Association Edward Livingston Trudeau Scholar and recipient of the Cystic Fibrosis Foundation (CFF) LeRoy Matthew’s Physician-Scientist Award, his research has focused on characterizing genetic and molecular factors that contribute to lung disease in cystic fibrosis and primary ciliary dyskinesia. With past and continued support from the National Institutes of Health (NIH), CFF, and March of Dimes, Dr. Ferkol and his collaborators are studying the origins and potential therapeutic targets for these inherited airway diseases. He is an investigator for the NIH-supported Genetic Diseases of Mucociliary Clearance Consortium, and has assembled clinical, biomedical, and engineering research collaborative at Washington University, studying the genetic and phenotypic spectrum of ciliopathies. He is also co-principal investigator on a NIH-funded program that is examining adverse respiratory outcomes in children with chronic lung disease related to prematurity. Dr. Ferkol has been an active member of the American Thoracic Society (ATS), serving as the chair of the Scientific Assembly on Pediatrics and chair of its program committee. He was recently installed as president of the ATS, only the second pediatrician in the 110 years of the Society. He has been a member of several scientific review groups, including the NIH Gene and Drug Delivery Study Section, ATS Career Development Grants Review Committee, CFF Research Development Program Review Committee and CFF Functional Genomics Review Committee. Finally, he serves as a member of the American Board of Pediatrics Subboard of Pediatric Pulmonology.


  • BA, magna cum laude, Case Western Reserve University1981
  • MB, University of Nottingham, School of Biological Sciences1980
  • MD, Medicinae doctor, The Ohio State University College of Medicine1985


  • Intern, University of North Carolina at Chapel Hill1985 - 1986
  • Resident, University of North Carolina at Chapel Hill1986 - 1988
  • Chief Resident, University of North Carolina at Chapel Hill1988 - 1989
  • Pulmonology Fellow, Case Western Reserve University School of Medicine1989 - 1992

Licensure and Board Certification

  • Medical License, State of Illinois (temporary, active)
  • Medical License, State of Missouri (current)
  • Medical License, State of North Carolina (expired voluntarily)
  • Medical License, State of Ohio (expired voluntarily)
  • National Board of Medical Examiners, Diplomate
  • US Drug Enforcement Agency, Certified
  • 1990American Board of Pediatrics, General Pediatrics Diplomate, Certified (Re-certified, 1998, 2005)
  • 1994American Board of Pediatrics, Pediatric Pulmonology Subboard Diplomate (Re-certified, 2002, 2009)

Honors and Awards

  • Cystic Fibrosis Foundation LeRoy Matthews Physician-Scientist Award1989
  • Floyd Denny Pediatric Alumni Society Award, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina1989
  • Rainbow Babies and Children’s Hospital Trustees New Investigator Award1992
  • American Lung Association Edward Livingston Trudeau Scholar1994
  • Teaching Excellence Award, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio1994
  • Society for Pediatric Research, member1997
  • Best Doctors of America®1998 - Pres
  • EDI Innovation Award.1999
  • European Cystic Fibrosis Conference Presentation Award2004
  • America's Top Pediatricians, Consumer's Research Council of America2006 - Pres
  • American Pediatric Society, member2009 - Pres
  • Alexis Hartmann MD Professorship Award2012
  • Vanderbilt University Thomas Hazinski MD Lectureship, Nashville, Tennessee2019
  • Primary Ciliary Dyskinesia Foundation Founders (Golden Cilium) Award2019
  • Primary Ciliary Dyskinesia Foundation Golden Cilium Award2019
  • Vanderbilt University Thomas Hazinski MD Lectureship, Nashville, Tennessee2019

Recent Publications view all (173)

  1. An Adolescent with Respiratory Distress. J Allergy Clin Immunol Pract. 2021;9(12):4502-4504. PMID:34893195 
  2. Lung inflammation and simulated airway resistance in infants with cystic fibrosis. Respir Physiol Neurobiol. 2021;293:103722. PMCID:PMC8330801  PMID:34157384 
  3. Hyperinflation is associated with increased respiratory rate and is a more sensitive measure of cystic fibrosis lung disease during infancy compared to forced expiratory measures. Pediatr Pulmonol. 2021;56(9):2854-2860. PMCID:PMC8373786  PMID:34143539 
  4. Emerging Genotype-Phenotype Relationships in Primary Ciliary Dyskinesia. Int J Mol Sci. 2021;22(15). PMCID:PMC8348038  PMID:34361034 
  5. Advances in the Diagnosis and Treatment of Primary Ciliary Dyskinesia: A Review. JAMA Otolaryngol Head Neck Surg. 2021. PMID:34137802 
  6. Implementation of a screening tool for primary ciliary dyskinesia (PCD) in a pediatric otolaryngology clinic. Int J Pediatr Otorhinolaryngol. 2021;142:110586. PMCID:PMC8021076  PMID:33388601 
  7. Understanding Primary Ciliary Dyskinesia and Other Ciliopathies. J Pediatr. 2021;230:15-22.e1. PMID:33242470 
  8. Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable. Front Pediatr. 2021;8:608821. PMCID:PMC7830672  PMID:33505947 
  9. Unfriendly Fire: How the Tobacco Industry is Destroying the Future of Our Children. Acta Med Litu. 2021;28(1):6-18. PMCID:PMC8311841  PMID:34393624 
  10. Pediatric lung transplantation: Dynamics of the microbiome and bronchiolitis obliterans in cystic fibrosis. J Heart Lung Transplant. 2020;39(8):824-834. PMCID:PMC7437357  PMID:32580896 
  11. A proposal for the addressing the needs of the pediatric pulmonary work force. Pediatr Pulmonol. 2020;55(8):1859-1867. PMCID:PMC7433343  PMID:32531116 
  12. Limitations of Nasal Nitric Oxide Testing in Primary Ciliary Dyskinesia. Am J Respir Crit Care Med. 2020;202(3):476-477. PMCID:PMC7397801  PMID:32329626 
  13. High-Speed Videomicroscopy Analysis Presents Limitations in Diagnosis of Primary Ciliary Dyskinesia. Am J Respir Crit Care Med. 2020;201(1):122-123. PMCID:PMC6938157  PMID:31433949 
  14. De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry. Am J Hum Genet. 2019;105(5):1030-1039. PMCID:PMC6849114  PMID:31630787 
  15. Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium. J Pediatr. 2019;208:148-155.e3. PMCID:PMC6486865  PMID:30857774 
  16. Air pollution in the Asia-Pacific Region: A Joint Asian Pacific Society of Respirology/American Thoracic Society perspective (Republication). Respirology. 2019;24(5):484-491. PMID:30920029 
  17. Black Race Is Associated with a Lower Risk of Bronchopulmonary Dysplasia. J Pediatr. 2019;207:130-135.e2. PMCID:PMC6458591  PMID:30612812 
  18. Prevention of cystic fibrosis: The beginning of the end? Sci Transl Med. 2019;11(485). PMID:30918110 
  19. Air Pollution in the Asia-Pacific Region. A Joint Asian Pacific Society of Respirology/American Thoracic Society Perspective. Am J Respir Crit Care Med. 2019;199(6):693-700. PMID:30508489 
  20. Early respiratory viral infections in infants with cystic fibrosis. J Cyst Fibros. 2019. PMID:30826285 
  21. Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. Am J Respir Crit Care Med. 2019;199(2):190-198. PMCID:PMC6353004  PMID:30067075 
  22. Patient, Family, and Center-Based Factors Associated with Attrition in Neonatal Clinical Research: A Prospective Study. Neonatology. 2019;115(4):328-334. PMCID:PMC6657796  PMID:30836358 
  23. Differences in the lower airway microbiota of infants with and without cystic fibrosis. J Cyst Fibros. 2018. PMCID:PMC6586525  PMID:30580994 
  24. Exome sequencing identifies gene variants and networks associated with extreme respiratory outcomes following preterm birth. BMC Genet. 2018;19(1):94. PMCID:PMC6195962  PMID:30342483 
  25. Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;197(12):e24-e39. PMCID:PMC6006411  PMID:29905515 
  26. Functional characterization of biallelic RTTN variants identified in an infant with microcephaly, simplified gyral pattern, pontocerebellar hypoplasia, and seizures. Pediatr Res. 2018. PMID:29967526 
  27. Acute Responses to Diuretic Therapy in Extremely Low Gestational Age Newborns: Results from the Prematurity and Respiratory Outcomes Program Cohort Study. J Pediatr. 2018;197:42-47.e1. PMCID:PMC5970973  PMID:29599068 
  28. Advances in the Genetics of Primary Ciliary Dyskinesia: Clinical Implications. Chest. 2018. PMID:29800551 
  29. Electronic cigarette use in youths: a position statement of the Forum of International Respiratory Societies. Eur Respir J. 2018;51(5). PMID:29848575 
  30. Comment on: Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2018;65(1). PMID:28834235 
  31. Twenty Facts About Cystic Fibrosis. Am J Respir Crit Care Med. 2017;196(12):P23-P24. PMID:29243949 
  32. Growth and nutritional status, and their association with lung function: a study from the international Primary Ciliary Dyskinesia Cohort. Eur Respir J. 2017;50(6). PMID:29269581 
  33. Movement. Paediatr Respir Rev. 2017;24:19-20. PMID:28687245 
  34. Bronchopulmonary Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at Extremely Low Gestational Age: A Prospective Cohort Study. J Pediatr. 2017;187:89-97.e3. PMCID:PMC5533632  PMID:28528221 
  35. Association of Antibiotics, Airway Microbiome and Inflammation in Infants with Cystic Fibrosis. Ann Am Thorac Soc. 2017;14:1548-1555. PMID:28708417 
  36. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. Thorax. 2017. PMID:28280235 
  37. Thoracoabdominal Asynchrony Is Not Associated with Oxyhemoglobin Saturation in Recovering Premature Infants. Neonatology. 2017;111(4):297-302. PMCID:PMC5443694  PMID:28013296 
  38. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Ann Am Thorac Soc. 2016;13(8):1305-13. PMID:27070726 
  39. Primary Ciliary Dyskinesia: First Health-r